If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Cyramza ® (ramucirumab) injection
10 mg/mL solution
The below information is provided in response to your request and may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above.
CYRAMZA® (ramucirumab): Indications for Use
Cyramza (ramucirumab) is indicated for the treatment of patients with gastric/GEJ adenocarcinoma, NSCLC and mCRC.
CYRAMZA® (ramucirumab): Indications for Use
Ramucirumab is a human VEGFR-2 antagonist indicated:
as a single agent or in combination with paclitaxel, for treatment of advanced gastric or GEJ adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.1
in combination with docetaxel, for treatment of metastatic NSCLC with disease progression on or after platinum-based chemotherapy.1
Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving ramucirumab.1
in combination with FOLFIRI, for the treatment of mCRC with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.1
Enclosed Prescribing Information
CYRAMZA® (ramucirumab) injection, for intravenous use, Lilly
1. Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2017.
Glossary
ALK = anaplastic lymphoma kinase
GEJ = gastroesophageal junction
EGFR = epidermal growth factor receptor
FDA = Food and Drug Administration
FOLFIRI = irinotecan, folinic acid, and 5-fluorouracil
mCRC = metastatic colorectal cancer
NSCLC = non-small cell lung cancer
VEGFR-2 = vascular endothelial growth factor receptor 2
Date of Last Review: February 12, 2018
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 8pm ET
